Aurora Investment Counsel Sells 118 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Aurora Investment Counsel cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,437 shares of the company’s stock after selling 118 shares during the quarter. Aurora Investment Counsel’s holdings in Neurocrine Biosciences were worth $1,437,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Mather Group LLC. purchased a new position in Neurocrine Biosciences in the 1st quarter worth approximately $26,000. RFP Financial Group LLC lifted its holdings in shares of Neurocrine Biosciences by 346.5% in the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after buying an additional 149 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of Neurocrine Biosciences during the second quarter worth $28,000. Innealta Capital LLC purchased a new position in Neurocrine Biosciences during the second quarter valued at $30,000. Finally, New Covenant Trust Company N.A. bought a new stake in Neurocrine Biosciences in the 1st quarter valued at $32,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $115.22 on Tuesday. The business’s 50-day moving average is $135.50 and its 200 day moving average is $137.42. Neurocrine Biosciences, Inc. has a 1 year low of $103.63 and a 1 year high of $157.98. The firm has a market capitalization of $11.60 billion, a P/E ratio of 31.74 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.52). The company had revenue of $590.20 million during the quarter, compared to analysts’ expectations of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The business’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.95 earnings per share. On average, analysts expect that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current year.

Insider Transactions at Neurocrine Biosciences

In other news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director William H. Rastetter sold 14,250 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the sale, the director now directly owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Julie Cooke sold 900 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $150.04, for a total transaction of $135,036.00. Following the transaction, the insider now owns 18,202 shares of the company’s stock, valued at $2,731,028.08. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,798 shares of company stock worth $9,274,196. Company insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on NBIX. BMO Capital Markets dropped their price objective on shares of Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating for the company in a report on Thursday, August 29th. Robert W. Baird raised their price target on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Morgan Stanley upped their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, July 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, August 29th. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $162.20.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.